舌下神经刺激器超FDA适应证患者的结果
本研究纳入18例不符合FDA舌下神经刺激器适应证的阻塞性睡眠呼吸暂停患者作为挽救性植入,评估其疗效。结果显示中位AHI从25.3降至3.75次/小时,ESS从11降至7.5,83.3%达到手术成功,结论认为成功率与STAR试验相似。
要点
- 超适应证植入舌下神经刺激器手术成功率为83.3%,与STAR试验1年结果66%相似。
- 中枢性呼吸暂停指数>25%的2例患者均未成功治疗。
- 中位依从性为33.5小时/周,提示超适应证患者仍可获益。
核心结论
- 超FDA指南行舌下神经刺激器植入的成功率为67%,与STAR试验1年结果66%相似。
- 未来需研究是否扩大舌下神经刺激器的适应证范围。
研究设计与样本
- 回顾性病例系列,纳入18例不符合FDA舌下神经刺激器适应证的阻塞性睡眠呼吸暂停患者。
- 比较术前与术后多导睡眠图参数、Epworth嗜睡评分及BMI。
主要发现
- 中位AHI从25.3降至3.75次/小时(P = .0006)。
- 最低血氧饱和度从82%升至88.5%(P = .0001)。
- 中位ESS从11降至7.5(P = .0016)。
- 15例(83.3%)达到手术成功(AHI下降>50%且AHI<20次/小时),12例(66.7%)AHI<5次/小时。
- 中枢性呼吸暂停指数>25%的2例患者均未成功治疗,中位依从性为33.5小时/周。
关键数值与推荐
- FDA适应证:AHI>15且≤65次/小时,中枢性呼吸暂停指数<25%的AHI,药物诱导睡眠内镜下无完全同心圆塌陷,推荐BMI<32 kg/m2。
- 手术成功定义:AHI下降>50%且AHI<20次/小时。
临床怎么用
- 对于不符合FDA适应证的患者,舌下神经刺激器可作为挽救性治疗选择,但中枢性呼吸暂停指数>25%者可能疗效不佳。
局限性
- 样本量小(18例),证据等级为4级。
- 回顾性设计,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The hypoglossal nerve stimulator (HGNS) is currently approved for the treatment of obstructive sleep apnea (OSA) in patients with an apnea-hypopnea index (AHI) of >15 to ≤65 events/hour, and a central apnea index (CAI) <25% of the AHI, no complete concentric collapse on drug-induced sleep endoscopy, and a recommended body mass index (BMI) <32 kg/m2 . We present 18 patients implanted as a salvage procedure despite being outside these guidelines. METHODS: We included all patients who underwent HGNS but who did not meet all FDA guidelines. Demographic data, previous OSA treatments, polysomnographic (PSG) parameters from baseline and HGNS titration PSG, Epworth sleepiness score (ESS), and BMI were compared before and after surgery. RESULTS: Eighteen patients were identified: 94.4% male, median age 63 years. Seven underwent previous sleep surgery. Four had an AHI <15 (mean 10.5 events/hour), four had an AHI >65 (mean 86.9 events/hour), two had an elevated CAI (mean 31.3% of AHI), and 12 had a BMI >32 kg/m2 (range 32.1-39.1). Median AHI decreased from 25.3 to 3.75 events/hour on titration polysomnography (P = .0006), oxyhemoglobin saturation nadir increased from 82% to 88.5% (P = .0001) and median ESS dropped from 11 to 7.5 (P = .0016). Fifteen (83.3%) patients achieved surgical success (decrease in AHI >50% and AHI <20 events/hour) and 12 (66.7%) had an AHI <5 events/hour. Neither patient with CAI >25% was successfully treated. Median adherence = 33.5 hours/week. CONCLUSION: Our success rate for patients outside the Food and Drug Administration guidelines for HGNS (67%) was similar to the 1-year STAR trial results (66%). Future studies are necessary to consider expansion of these guidelines. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:866-872, 2020.
引用
- Sarber KM, Chang KW, Ishman SL, et al. Hypoglossal Nerve Stimulator Outcomes for Patients Outside the U.S. FDA Recommendations. Laryngoscope. 2019. PMID: 31291013. doi:10.1002/lary.28175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。